The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer

Biochemical and Biophysical Research Communications

Volumn 422, Issue 4, 2012, Pages 676-680

  Tang, Xiao han ^a   Deng, Suo ^a   Li, Meng ^a   Lu, Mei song ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Chemoresistance; Cross reacting material; Heparin binding epidermal growth factor like growth factor; Ovarian cancer

Indexed keywords

CISPLATIN; DIPHTHERIA TOXOID CRM197; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TUMOR XENOGRAFT; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BACTERIAL PROTEINS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84862293340     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.052     Document Type: Article

References (22)

1. Ishibashi M., Nakayama K., Yeasmin S., Katagiri A., Iida K., Nakayama N., Fukumoto M., Miyazaki K. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer. Clin. Cancer Res. 2008, 14:3149-3155.
2. Nanba D., Higashiyama S. Dual intracellular signaling by proteolytic cleavage of membrane-anchored heparin-binding EGF-like growth factor. Cytokine Growth Factor Rev. 2004, 15:13-19.
3. Miyamoto S., Yagi H., Yotsumoto F., Horiuchi S., Yoshizato T., Kawarabayashi T., Kuroki M., Mekada E. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule. Anticancer Res. 2007, 27:3713-3721.
4. Iwamoto R., Mekada E. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev. 2000, 11:335-344.
5. Nishi E., Klagsbrun M. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a mediator of multiple physiological and pathological pathways. Growth Factors 2004, 22:253-260.
6. Kinugasa Y., Hieda M., Hori M., Higashiyama S. The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J. Biol. Chem. 2007, 282:14797-14806.
7. Ongusaha P.P., Kwak J.C., Zwible A.J., Macip S., Higashiyama S., Taniguchi N., Fang L., Lee S.W. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res. 2004, 64:5283-5290.
8. Sanui A., Yotsumoto F., Tsujioka H., Fukami T., Horiuchi S., Shirota K., Yoshizato T., Kawarabayashi T., Kuroki M., Miyamoto S. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. Anticancer Res. 2010, 30:3143-3149.
9. Hatakeyama H., Cheng H., Wirth P., Counsell A., Marcrom S.R., Wood C.B., Pohlmann P.R., Gilbert J., Murphy B., Yarbrough W.G., Wheeler D.L., Harari P.M., Guo Y., Shyr Y., Slebos R.J., Chung C.H. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 2010, 5:e12702.
10. Tsujioka H., Yotsumoto F., Hikita S., Ueda T., Kuroki M., Miyamoto S. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Curr. Opin. Obstet. Gynecol. 2011, 23:24-30.
11. Miyamoto S., Hirata M., Yamazaki A., Kageyama T., Hasuwa H., Mizushima H., Tanaka Y., Yagi H., Sonoda K., Kai M., Kanoh H., Nakano H., Mekada E. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 2004, 64:5720-5727.
12. Yagi H., Miyamoto S., Tanaka Y., Sonoda K., Kobayashi H., Kishikawa T., Iwamoto R., Mekada E., Nakano H. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br. J. Cancer 2005, 92:1737-1745.
13. Yagi H., Yotsumoto F., Miyamoto S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol. Cancer Ther. 2008, 7:3441-3451.
14. Wang F., Liu R., Lee S.W., Sloss C.M., Couget J., Cusack J.C. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 2007, 26:2006-2016.
15. Suganuma K., Kubota T., Saikawa Y., Abe S., Otani Y., Furukawa T., Kumai K., Hasegawa H., Watanabe M., Kitajima M., Nakayama H., Okabe H. Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci. 2003, 94:355-359.
16. Fang L., Li G., Liu G., Lee S.W., Aaronson S.A. P53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J. 2001, 20:1931-1939.
17. Buzzi S., Rubboli D., Buzzi G., Buzzi A.M., Morisi C., Pironi F. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol. Immunother. 2004, 53:1041-1048.
18. Miyamoto S., Yagi H., Yotsumoto F., Kawarabayashi T., Mekada E. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci. 2006, 97:341-347.
19. Yagi H., Yotsumoto F., Sonoda K., Kuroki M., Mekada E., Miyamoto S. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int. J. Cancer 2009, 124:1429-1439.
20. Tsujioka H., Fukami T., Yotsumoto F., Ueda T., Hikita S., Takahashi Y., Kondo H., Kuroki M., Miyamoto S. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer. Anticancer Res. 2011, 31:2461-2465.
21. Lu M., Xiao L., Li Z. The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells. J. Huazhong Univ. Sci. Technol. Med. Sci. 2007, 27:725-728.
22. Scambia G., Benedetti Panici P., Battaglia F., Ferrandina G., Baiocchi G., Greggi S., De Vincenzo R., Mancuso S. Significance of epidermal growth factor receptor in advanced ovarian cancer. J. Clin. Oncol. 1992, 10:529-535.